CHK1i ADC / Cancentus Pharma - LARVOL DELTA

First-in-class CHK1 inhibitor antibody-drug conjugate overcomes limitations of current ADC payloads and provides a new option for HER2-positive and TOP1 inhibitor-resistant tumors (AACR 2026) - "The novel payload exploits the presence of DNA replication stress in cancer, leading to greater selectivity.Trastuzumab variants containing engineered cysteines were generated to enable site-specific conjugation. This first-in-class CHK1i ADC expands payload diversity, aims to address resistance to existing ADCs and reduce nonspecific toxicity, offering the potential for a wider therapeutic window."

ADC • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • TOP1